Abstract
To evaluate and compare the effects of topical application and subconjunctival injection of bevacizumab on corneal neovascularization (CNV) in rabbits' eyes after chemical burning of the cornea. The animals were randomly distributed into four groups of five animals. In one group, the drug was instilled, while in another, it was administered by subconjunctival injection. The two procedures using bevacizumab were compared with instillation and subconjunctival injection of saline solution (S). Neovascularization was evaluated according to the size of the invasion area of new blood vessels and through computerized analysis of this area. The data were analyzed using the Kruskal-Wallis test followed by Dunn's test for two-by-two comparison of the groups, to assess the external examination of CNV. Analysis of variance was used to assess the area of CNV. P<0.05 was considered statistically significant. Assessing both the external examination and the invasion area of neovessels on the 5th and 10th days, there was a clear difference between the groups. The group to which saline solution had been applied showed higher scores for CNV, as well as increases in the invasion area of neovessels. Two-by-two comparison of groups revealed no significant differences. However, an analysis of the factors involved (injection vs. instillation and bevacizumab vs. saline solution) showed that injection did not differ from instillation, but that bevacizumab differed from saline solution. Bevacizumab showed an inhibitory effect on CNV in rabbits' eyes after chemical burning of the cornea. There was no difference between the topical or subconjunctival administration of bevacizumab in the inhibition of CNV.
Highlights
Studies of bevacizumab for topical use in the eye are opportune given that inhibition of the growth of neovessels on the ocular surface is desirable in numerous situations
Corneal neovascularization (CNV) depends on the balance between vascular growth factors and inhibitory vascular growth factors present in the vascular endothelium[4]
Cell proliferation occurs in the vascular endothelium, which depends on the vascular endothelial growth factor (VEGF)(5-6)
Summary
Studies of bevacizumab for topical use in the eye are opportune given that inhibition of the growth of neovessels on the ocular surface is desirable in numerous situations. Corneal neovascularization (CNV) is a response of the cornea to injury or inflammation. Cell proliferation occurs in the vascular endothelium, which depends on the vascular endothelial growth factor (VEGF)(5-6). Bevacizumab is defined as an antineoplastic agent; it is a huma nized monoclonal antibody that inhibits angiogenesis, acting as specific inhibitor of VEGF[7,8,9]. It was approved by the Food and Drug Administration in 2004 for use in metastatic colon cancer administered via the systemic route[4,8,10]. This drug is administered via the intraocular route, and in off-label use, age-related macular degene-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
